Bajaj Healthcare is currently trading at Rs. 673.60, up by 37.55 points or 5.90% from its previous closing of Rs. 636.05 on the BSE.
The scrip opened at Rs. 635.65 and has touched a high and low of Rs. 675.00 and Rs. 635.50 respectively. So far 215402 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 675.00 on 28-May-2021 and a 52 week low of Rs. 250.00 on 29-May-2020.
Last one week high and low of the scrip stood at Rs. 675.00 and Rs. 591.05 respectively. The current market cap of the company is Rs. 925.86 crore.
The promoters holding in the company stood at 67.26%, while Non-Institutions held 32.74% stake in the company.
Bajaj Healthcare has launched ‘Posaconazole API’ used in treating Mucormycosis (Black Fungus) infection in Covid-19 patients. The company has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market ‘Posaconazole API’ as approved medication for treating Mucormycosis in India and it will commence its commercial production from first week of June 2021.
Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post Covid complications. Black fungus is a deadly fungal infection and has triggered a new health challenge in the country. More than 11,000 cases of black fungal infection have been reported from different parts, forcing state governments to declare it an epidemic.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1800.30 |
Dr. Reddys Lab | 1275.05 |
Cipla | 1472.05 |
Lupin | 2098.70 |
Zydus Lifesciences | 979.10 |
View more.. |